Protection against Plasmodium falciparum malaria by PfSPZ Vaccine.

PubWeight™: 0.86‹?›

🔗 View Article (PMID 28097230)

Published in JCI Insight on January 12, 2017

Authors

Judith E Epstein1, Kristopher M Paolino2, Thomas L Richie3, Martha Sedegah1, Alexandra Singer1, Adam J Ruben3, Sumana Chakravarty3, April Stafford2, Richard C Ruck2, Abraham G Eappen3, Tao Li3, Peter F Billingsley3, Anita Manoj3, Joana C Silva4, Kara Moser4, Robin Nielsen2, Donna Tosh2, Susan Cicatelli2, Harini Ganeshan1, Jessica Case5, Debbie Padilla3, Silas Davidson2, Lindsey Garver2, Elizabeth Saverino3, Tooba Murshedkar3, Anusha Gunasekera3, Patrick S Twomey2, Sharina Reyes1, James E Moon2, Eric R James3, Natasha Kc6, Minglin Li6, Esteban Abot1, Arnel Belmonte1, Kevin Hauns2, Maria Belmonte1, Jun Huang1, Carlos Vasquez1, Shon Remich2, Mary Carrington1, Yonas Abebe3, Amy Tillman5, Bradley Hickey2, Jason Regules2, Eileen Villasante1, B Kim Lee Sim6, Stephen L Hoffman3

Author Affiliations

1: Naval Medical Research Center (NMRC).
2: Walter Reed Army Institute of Research (WRAIR), Silver Spring, Maryland, USA.
3: Sanaria Inc., Rockville, Maryland, USA.
4: Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
5: Statistics Collaborative Inc., Washington, DC, USA.
6: Sanaria Inc., Rockville, Maryland, USA.; Protein Potential, Rockville, Maryland, USA.

Associated clinical trials:

A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses | NCT02215707

PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults | NCT02601716

Articles cited by this

Genetic analysis of the human malaria parasite Plasmodium falciparum. Science (1987) 6.48

Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature (1988) 5.99

Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet (2008) 5.49

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis (2002) 5.43

Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72

CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A (1988) 4.67

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (2013) 4.60

Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature (1989) 4.08

Protection against a malaria challenge by sporozoite inoculation. N Engl J Med (2009) 4.03

The complexity of protective immunity against liver-stage malaria. J Immunol (2000) 2.92

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis (2005) 2.66

Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature (1988) 2.56

Circumsporozoite proteins of malaria parasites. Cell (1985) 2.45

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin (2010) 2.36

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol (2003) 2.32

Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg (1984) 2.31

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med (2015) 2.18

Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science (1989) 2.09

Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med (1990) 2.09

Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med (1986) 1.51

Chloroquine sensitivity of isolates of Plasmodium falciparum adapted to in vitro culture. Trop Geogr Med (1981) 1.39

Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg (1993) 1.34

Multiplex qPCR for detection and absolute quantification of malaria. PLoS One (2013) 1.27

Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One (2012) 1.16

Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection. J Clin Microbiol (1989) 1.07

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med (2016) 1.06

Sample-ready multiplex qPCR assay for detection of malaria. Malar J (2014) 0.91